PTO/SB/30 (07-09) Approved for use through 07/31/2012, OMR 0651-0031

Request for Continued Examination (RCE) Transmittal  Address to:  May 24, 2006 Filling Date First Named Inventor  At Unit  Examiner Name  Transmittal  Transmittal  At Unit  Examiner Name  Transmittal  Transmittal  At Unit  Examiner Name  Transmittal Nation  Transmittal Nation  Transmittal Nation  At Unit  Examiner Name  Transmittal Nation  Transmittal Nation  Transmittal Nation  At Unit  Examiner Name  Transmittal Nation  Transmittal Nation  Transmitt	Under the Paper	work Reduction Act of 1995, no persons are requir	U.S. Patent and red to respond to a collection of in	Trademark Office; U.S	S. DEPARTMENT OF COMMERCE	
Filing Date    Filing Date						
Transmittal Address to Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  This is a Request for Continued Examination (RCE) ander 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) ander 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) ander 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) ander 37 CFR 1.114 (Note: the RCE is upper, any proviously filled unnettered amendments and amendments and a submission required under 37 CFR 1.114 (Note: the RCE is upper, any proviously filled unnettered amendments (Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	for			May 24, 200	6	
Add Unit 4372  Mail Stop RCE Commissioner for Patents P.O. Box 1430 Alexandria, VA 22313-1450  This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) under 37 CFR 1.114 does not apply to any utility or plant application fled prior to Jul 1985, or to aim dealth application. See instruction Sheet for RCEs inde to be submitted to the USPTO) on page 2.    Submission required under 37 CFR 1.114 (Note: the RCE is proper, any previously filled underted amendments) and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filled underted amendment(s) entered, applicant most request non-entry of applicant most request non-entry of applicant most applicant on application is on some different previously will applicate the final Office action may be considered as a submission even if this box is not checked.    Consider the arguments in the Appeal Brief or Reply Brief previously filled on				Shinya Taka	gi	
Commissioner for Patents P.O. Bos 1450 Alexandria, VA 22313-1450  Examiner Name Attorney Docket Number 144620-144  This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application fleed prior to July 1985, or to ariv dealth application. See instruction Sheet for RCEs index to be submitted to the USFTO) on page 2.    Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filled underted amendments and application in the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filled underted amendment(s) entered, applicant must request non-entry to an amendment(s).    Consider the arguments in the Appeal Brief or Reply Brief previously filled on	Address to:		Art Unit	4372		
Altorney Docket Number   494620-144	Commissioner for Patents		Examiner Name	Torres Ruiz,	Johali Alejandra	
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to Ju 1996, or to any design application. See Instruction Share for RCEs (not be submitted to the USPTO) on page 2.  1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and control in the RCE will be emired in the order in which they were filed unders 37 certain instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).  a.	Alexandria, VA 22313-1450		Attorney Docket Numl	oer 434620-144		
amendments enclosed with the RCE will be entered in the order in which they were flet unless applicant instructs otherwise. If applicant does not wish to have any previously filed unnetered amendment(s) entered, applicant must request non-entry of such amendment(s).  a Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on i. Other  b. Aftidavit(s) Declaration(s) iii. Information Disclosure Statement (IDS)  iii. Other  2. Miscellaneous  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. Period of suspension shall not exceed 3 months. Fee under 37 CFR 1.17(i) required)  b. Other  3. Fees  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments as Deposit Account No. 50.3557  i. RCE fee required under 37 CFR 1.17(e)  iii. Extension of time fee (37 CFR 1.136 and 1.17)  iii. Other  D. Check in the amount of \$	Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.					
a. Consider the arguments in the Appeal Brief or Reply Brief previously filed on    Consider the arguments in the Appeal Brief or Reply Brief previously filed on   I	amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such					
Delta   Delt						
b.	Consider the arguments in the Appear Sher of Reply Sher previously med on					
ii.						
2. Miscellaneous  a	I. Amendment/Reply iii. Information Disclosure Statement (IDS)					
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of	ii. 🔲	Affidavit(s)/ Declaration(s)	iv. Other			
The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments peoposit Account No. 50-3557  i. V RCE fee required under 37 CFR 1.17(e)  ii. Extension of time fee (37 CFR 1.136 and 1.17)  iii. Other  b. Check in the amount of \$endosed  c. Payment by credit card (Fom PTO-2038 endosed)  WARNING: Information and authorization on PTO-2038.  Signature // Khaled Shami/ Signature // Khaled Shami/ Signature // Khaled Shami/ Date // March 31, 2010	Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a  3. period ofmonths, (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)					
a. V Deposit Account No. 50-3557 i. V RCE fee required under 37 CFR 1.17(e) ii. Extension of time fee (37 CFR 1.136 and 1.17) iii. Other b. Check in the amount of \$						
ii.						
iii. Other  b. Check in the amount of \$enclosed  c. Payment by credit card (Form PTC-2038 enclosed)  WARNINCS: Information on this form may become public. Credit card information should not be included on this form. Provide card information and authorization on PTC-2038.  Signature  Signature  //Khaled Shami/ March 31, 2010						
b. Check in the amount of \$endosed  c. Payment by credit card (Form PTC-2038 endosed)  WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide card information and authorization on PTC-2038.  Signature //Khaled Shami/ Date March 31, 2010						
c. Payment by credit card (Form PTO-2038 endosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide card information and authorization on PTO-2038.  Signature //Khaled Shami/ Date March 31, 2010						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide card information and authorization on PTO-2038.  Signature // Khaled Shami/ March 31, 2010						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Signature //Khaled Shami/ Date March 31, 2010	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit					
Signature /Khaled Shami/ Date March 31, 2010						
Name (Print/Type) Khaled Shami (VIA FFS) Registration No.   32 745				Date	March 31, 2010	
1,500.00 0.00111(410.00)	Name (Print/Type)	Khaled Shami (VIA EFS)		Registration No.	38,745	
CERTIFICATE OF MAILING OR TRANSMISSION						
I hereby certify that this correspondence is being deposited with the United States Postal Sen/sc with sufficient postage as first class mail in an envelope addressed to Mail Stop RCE. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22315-1450 or faccimile transmitted to the U.S. Patent and Trade Office on the date shown below.						
Signature /Rachel Mena/						
Name (Print/Type) Rachel Mena (VIA EFS)  This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the	Name (Print/Type) R	achel Mena (VIA EFS)		March 31, 20	10	

to process) an application. Confidentially is governed by \$5 U.S.C. 122 and \$7 CPR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete including glathering, preparing, and submitting the completed application from the USPTO. The well way depending once in the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this bursten, should be sent to the Chel Information Officer, U.S. Fraient and Trademark Office. U.S. Department of Commence, P.G. Box 41450, Alexandra's U.S. 2231-14450, DOT'S EN D'EES DE COMPLETED FORMS TO "THIS ADDRESS SEND TO: Mall \$150 p.RCE, Commissioner for Patentis, P.O. Box 1450, Alexandris, VA 2231-1450. DOT'S EN D'EES D'ARDRESS SEND TO: Mall \$150 p.RCE, Commissioner for Patentis, P.O. Box 1450, Alexandris, VA 2231-1450.

If you need assistance in completing the form, and 17-800-PTO-1999 and select option 2.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or excitation or the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.SC., 5524/m1.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as gent of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.